Old Drugs for New Indications in Cardiovascular Medicine

Yaron Arbel; Wael Abuzeid; Robert S. Rosenson; Alanna Weisman; Michael E. Farkouh

doi:10.1007/s10557-018-6785-y

Old Drugs for New Indications in Cardiovascular Medicine

Yaron Arbel^*, Wael Abuzeid, Robert S. Rosenson, Alanna Weisman, Michael E. Farkouh

^*Corresponding author for this work

Cardiology

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy.

Original language	English
Pages (from-to)	223-232
Number of pages	10
Journal	Cardiovascular Drugs and Therapy
Volume	32
Issue number	2
DOIs	https://doi.org/10.1007/s10557-018-6785-y
State	Published - 1 Apr 2018

Keywords

Allopurinol
Atherosclerosis
Cardiovascular disease
Colchicine
Inflammation
Methotrexate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10557-018-6785-y

Cite this

@article{98f3e24c6fee4b4b8451443397a8af2e,

title = "Old Drugs for New Indications in Cardiovascular Medicine",

abstract = "Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy.",

keywords = "Allopurinol, Atherosclerosis, Cardiovascular disease, Colchicine, Inflammation, Methotrexate",

author = "Yaron Arbel and Wael Abuzeid and Rosenson, {Robert S.} and Alanna Weisman and Farkouh, {Michael E.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = apr,

day = "1",

doi = "10.1007/s10557-018-6785-y",

language = "אנגלית",

volume = "32",

pages = "223--232",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Old Drugs for New Indications in Cardiovascular Medicine

AU - Arbel, Yaron

AU - Abuzeid, Wael

AU - Rosenson, Robert S.

AU - Weisman, Alanna

AU - Farkouh, Michael E.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy.

AB - Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy.

KW - Allopurinol

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Colchicine

KW - Inflammation

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=85045097200&partnerID=8YFLogxK

U2 - 10.1007/s10557-018-6785-y

DO - 10.1007/s10557-018-6785-y

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 29633048

AN - SCOPUS:85045097200

SN - 0920-3206

VL - 32

SP - 223

EP - 232

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 2

ER -

Old Drugs for New Indications in Cardiovascular Medicine

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this